Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.

Fyles, Fred; Nuttall, Amy; Joplin, Hannah; Burhan, Hassan

Fyles, Fred; Nuttall, Amy; Joplin, Hannah; Burhan, Hassan.

Afiliação

Fyles F; Liverpool University Hospitals National Health Service Foundation Trust, Liverpool, United Kingdom. Electronic address: fred.fyles@liverpoolft.nhs.uk.
Nuttall A; Liverpool University Hospitals National Health Service Foundation Trust, Liverpool, United Kingdom.
Joplin H; Liverpool University Hospitals National Health Service Foundation Trust, Liverpool, United Kingdom.
Burhan H; Liverpool University Hospitals National Health Service Foundation Trust, Liverpool, United Kingdom; Liverpool School of Tropical Medicine, Liverpool, United Kingdom; University of Liverpool, Liverpool, United Kingdom.

J Allergy Clin Immunol Pract ; 11(9): 2715-2723, 2023 09.

Article em En | MEDLINE | ID: mdl-37245734

Assuntos

Antiasmáticos; Asma; Produtos Biológicos; Eosinofilia Pulmonar; Humanos; Antiasmáticos/uso terapêutico; Qualidade de Vida; Estudos Retrospectivos; Asma/tratamento farmacológico; Asma/etiologia; Eosinofilia Pulmonar/tratamento farmacológico; Corticosteroides/uso terapêutico; Produtos Biológicos/uso terapêutico

Palavras-chave

Benralizumab; Mepolizumab; Monoclonal therapy; Oral corticosteroids; Severe eosinophilic asthma; Super-response

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Eosinofilia Pulmonar / Asma / Produtos Biológicos / Antiasmáticos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google